Institute of Chemical & Engineering Sciences (ICES), 1 Pesek Road, Jurong Island, Singapore 627833.
Future Med Chem. 2013 Apr;5(6):705-14. doi: 10.4155/fmc.13.47.
Recently, boron compounds have attracted increasing attention both in academic laboratories and in the pharmaceutical industry. Boron, in particular the (10)B isotope, has the unique capability of absorbing a slow neutron to initiate a nuclear reaction with release of energetic particles such as α- and Li-particles, which is not observed in its carbon analogues. The nuclear capture reaction concept has been adopted in radiation therapy and used in boron neutron capture therapy (BNCT). BNCT is a potentially promising treatment for malignant brain tumors as well as other cancers, despite the limitation of a scarcity of neutron sources. There is the need in advanced research centers to construct high boron-containing composites as BNCT agents and develop more efficient drug carriers. This review discusses recent works on the development of boron-based therapeutic nanomaterials as BNCT agents.
最近，硼化合物在学术实验室和制药行业都引起了越来越多的关注。硼，特别是 （10）B 同位素，具有独特的能力，可以吸收慢中子，引发核反应，并释放出 α-和 Li-粒子等高能粒子，而其碳类似物则没有这种能力。核俘获反应的概念已被应用于放射治疗，并用于硼中子俘获治疗（BNCT）。尽管中子源稀缺，但 BNCT 仍然是治疗恶性脑肿瘤和其他癌症的一种很有前途的治疗方法。在先进的研究中心，需要构建高含硼复合材料作为 BNCT 试剂，并开发更有效的药物载体。本综述讨论了最近在开发硼基治疗性纳米材料作为 BNCT 试剂方面的工作。
